Study reveals shortfalls in federal regulatory oversight of synthetic biology output

06/3/2014 | Bloomberg BNA (free content)

New techniques in biotech and synthetic biology are leading to less federal oversight, according to a study from the J. Craig Venter Institute. The study says the federal Animal and Plant Health Inspection Service lacks the authority to review organisms synthesized using newer methods, while the Environmental Protection Agency needs more financial support and expertise to keep up with the rise of biotech organisms. The institute suggested expanding the oversight of the regulating agencies and concentrating on the plants and organisms that present more risks.

View Full Article in:

Bloomberg BNA (free content)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC